AtaGenix

Hot search： CD47 │ IL6 │ PD-L1 │ CTLA-4 │ TIGIT
Current Site： Product Center / Recombinant Protein / Drug Targets / Recombinant Human VEGFA/VEGF protein ,N- MAT Tag

Recombinant Human VEGFA/VEGF protein ,N- MAT Tag

  • 1
  • 2
  • 3
ATEP00059HU
-
+
futures
Inquiry
  • Product Details
  • Frontier progress
  • How to order
  • Instructions
Summaryicon
English name
Recombinant Human VEGFA/VEGF protein ,N- MAT Tag
Purity
>90% as determined by SDS-PAGE
Endotoxin level
Please contact with the lab for this information.
Construction
A DNA sequence encoding the human VEGFA(Ala27~Arg136) was fused with the N-terminal MAT Tag
Accession #
P15692
Host
E.coli
Species
Homo sapiens (Human)
Predicted Molecular Mass
14.65kDa
Formulation
Supplied as solution form in PBS, pH 7.5 8M urea or lyophilized from PBS, pH 7.5 8M urea.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability &Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Bioactivityicon
    Backgroundicon
    Background
    VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
    Alternative Names
    RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
    References
    Vanderstraeten, Baselet, Buset, Ben Said, de Ville de Goyet, Many, Gérard, Derradji (2020) Modulation of VEGF Expression and Oxidative Stress Response by Iodine Deficiency in Irradiated Cancerous and Non-Cancerous Breast Cells International journal of molecular sciences 21(11)
    Breast cancer remains a major concern and its physiopathology is influenced by iodine deficiency (ID) and radiation exposure. Since radiation and ID can separately induce oxidative stress (OS) and microvascular responses in breast, their combination could additively increase these responses. Therefore, ID was induced in MCF7 and MCF12A breast cell lines by medium change. Cells were then X-irradiated with doses of 0.05, 0.1, or 3 Gy. In MCF12A cells, both ID and radiation (0.1 and 3 Gy) increased OS and vascular endothelial growth factor (VEGF) expression, with an additive effect when the highest dose was combined with ID. However, in MCF7 cells no additive effect was observed. VEGF mRNA up-regulation was reactive oxygen species (ROS)-dependent, involving radiation-induced mitochondrial ROS. Results on total VEGF mRNA hold true for the pro-angiogenic isoform VEGF165 mRNA, but the treatments did not modulate the anti-angiogenic isoform VEGF165b. Radiation-induced antioxidant response was differentially regulated upon ID in both cell lines. Thus, radiation response is modulated according to iodine status and cell type and can lead to additive effects on ROS and VEGF. As these are often involved in cancer initiation and progression, we believe that iodine status should be taken into account in radiation prevention policies.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.

    AtaGenix
    Copyright © 2024 Lawyer Theme All Rights Reserved
    Site map | Contact us | Join us